Carafate (Sucralfate) Indications
Carafate is FDA-approved for the short-term treatment (up to 8 weeks) of active duodenal ulcer. 1
FDA-Approved Indication
The only official FDA-approved indication for Carafate (sucralfate) suspension is:
- Active duodenal ulcer - short-term treatment for up to 8 weeks 1
This remains the sole indication for which the medication has regulatory approval, despite decades of clinical use in other conditions.
Off-Label Uses in Critical Care
While not FDA-approved for stress ulcer prophylaxis (SUP), sucralfate has been studied extensively in critically ill patients. However, current evidence does not favor sucralfate as a first-line agent for SUP 2:
- Sucralfate showed reduced pneumonia rates compared to PPIs (RR 0.49) and H2RAs (RR 0.83) 2
- However, many studies used outdated gastric pH targets (>3.5) that are no longer standard practice 2
- No evidence supports combining sucralfate with acid suppressants for SUP 2
- When used for SUP, the recommended dose is ≤4g daily 2
Important caveat: PPIs and H2RAs are generally preferred over sucralfate for stress ulcer prophylaxis in modern critical care practice, as they more effectively reduce clinically important upper GI bleeding 2.
Other Off-Label Applications
Research suggests potential benefits in various mucocutaneous conditions, though none are FDA-approved 3:
Topical sucralfate has shown clinical benefit in:
- Post-radiotherapy mucosal reactions 3, 4
- Radiation-induced proctosigmoiditis 5
- Recurrent aphthous stomatitis (71.4% improvement in one study) 6
- Postoperative oral surgical wounds (significant pain reduction on days 3 and 7) 7
- Diaper dermatitis and keratoconjunctivitis sicca 3
Oral/systemic uses studied (not FDA-approved):
Clinical Considerations
Contraindication: Known hypersensitivity to sucralfate or any excipients 1
Mechanism: Sucralfate works through multiple pathways including pepsin/bile acid adsorption, stimulation of bicarbonate and mucus secretion, prostaglandin synthesis, and mucosal protection 8. It forms a physical barrier over damaged epithelium 5.
Important limitation: Recent analysis questions the clinical value of sucralfate given the availability of more effective acid-suppressing medications, noting its continued high prescription rates despite limited evidence base 9.
Bottom line for prescribing: Stick to the FDA-approved indication of active duodenal ulcer unless using topically for mucocutaneous conditions where evidence supports benefit and other options have failed. For stress ulcer prophylaxis in ICU patients, prefer PPIs or H2RAs over sucralfate 2.